// GxP Service

EudraLex Annex 11 & FDA 21 CFR Part 11: Compliance for GxP Computerized Systems

Integrated gap assessment and remediation for simultaneous compliance with the EU and FDA regulatory frameworks governing electronic records and electronic signatures.

Why Annex 11 / 21 CFR Part 11 compliance matters

  • Computerized systems managing GxP records are subject to stringent regulatory requirements in Europe (Annex 11) and the USA (21 CFR Part 11)
  • Absence of correctly configured audit trails or access control is a critical finding in FDA and EMA inspections
  • A critical gap — such as non-compliant electronic signatures — can block product approvals or result in Warning Letters
  • Organizations operating in both jurisdictions must simultaneously satisfy both frameworks
  • An integrated assessment significantly reduces costs and timelines compared to two separate analysis campaigns
EudraLex Annex 11 and FDA 21 CFR Part 11: Compliance for GxP Computerised Systems

Our approach

Our structured three-phase Gap Assessment service delivers verifiable Compliance Readiness. We do not produce gap reports as an end in themselves: we build remediation pathways that organizations can actually complete.

Step 1 · Discovery

Discovery and documentation collection

  1. Complete inventory of GxP systems
  2. Review of existing validation documentation and system-related SOPs
  3. Analysis of user management records, audit trail configuration, backup procedures, and BCP/DRP
  4. Production of a complete map of the system estate and documentary maturity level
Step 2 · Assessment

Technical and regulatory assessment

  1. Structured evaluation of each system against Annex 11 and/or 21 CFR Part 11 requirements
  2. Gap identification across: validation, audit trail, access control, backup and restore, business continuity
  3. Gap severity classification (Critical / Major / Minor)
Step 3 · Remediation Plan

Gap Report and Remediation Plan

  1. Production of Gap Report with severity classification and normative mapping
  2. Remediation Plan with concrete actions, owners, timelines, and completion criteria
  3. Structured for management review and regulatory presentation
  4. Verifiable Compliance Readiness: current state, action plan, controlled gap management
DALIA IA IMPOSTA UN'IMMAGINE IN EVIDENZA

Deliverables and outputs

  • GxP system inventory
  • Gap Assessment Report (Critical / Major / Minor)
  • Remediation Plan with owners and timelines
  • Compliance Readiness Summary
  • Audit trail review SOPs
  • Access control and user management policies
  • Business Continuity Plan (BCP) template
  • Documentation for FDA, EMA, AIFA, ANSM inspections

Regulatory references

EudraLex Annex 11 (2011) FDA 21 CFR Part 11 ISPE GAMP 5 Second Edition (2022) ALCOA+ ICH Q9(R1)

Numbers that matter

20+
years of GxP experience

Studio active since 2004

900+
validated systems

Pharma, biotech, medical devices

40+
active clients

Multinationals and SMEs

100%
audit compliance

No open major findings

Who this is for

  • QA Manager
  • Validation Manager
  • IT Compliance Officer
  • Regulatory Affairs Manager
  • Data Integrity Officer
  • GxP Systems Manager

Operational benefits

Integrated EU/USA assessment

Our integrated assessment methodology evaluates compliance with both Annex 11 and 21 CFR Part 11 in a single engagement, significantly reducing costs and timelines compared to sequential analysis campaigns.

Concrete, actionable remediation

We do not produce gap reports as an end in themselves: we build remediation pathways with concrete actions, defined owners, and verifiable completion criteria that organizations can actually implement.

Inspection Readiness

The output is verifiable Compliance Readiness: the organization knows its exact gap profile and can demonstrate to inspectors that identified gaps are under controlled management.

Post-remediation continuity support

Our support does not end with Gap Report delivery: we accompany organizations in sustaining compliance over time through operating procedures, training, and periodic reviews.

EudraLex Annex 11 (2011) — Key Requirements

EudraLex Volume 4, Annex 11 governs the full lifecycle of computerized systems in EU GMP pharmaceutical manufacturing. Its core requirements span: Validation, Audit Trail, Access Control, Electronic Signatures, Data Storage and Backup, Business Continuity, Supplier Assessment, and Periodic Evaluation.

FDA 21 CFR Part 11 — Key Requirements

21 CFR Part 11 establishes the criteria under which the FDA considers electronic records and electronic signatures to be trustworthy, reliable, and equivalent to paper records and handwritten signatures. Key requirements include:

  • Closed systems (§11.10): unique user authentication, computer-generated audit trails with timestamps, access limitation, data backup, personnel training
  • Electronic signatures (§11.50, §11.100, §11.200): signatures must be uniquely bound to individuals; each signature must capture the signer’s name, date and time, and the meaning of the signature

Annex 11 vs 21 CFR Part 11: Key Differences

Both frameworks share the same fundamental objectives but differ in scope, prescriptive detail, and approach. Annex 11 is principles-based and risk-oriented; 21 CFR Part 11 is more prescriptive. Annex 11 explicitly requires supplier assessment; Part 11 does not. Our integrated assessment methodology evaluates compliance against both frameworks in a single engagement.

Audit Trail Review

A compliant audit trail must be automatically generated, tamper-proof, and retained for the full required period. It must record every creation, modification, and deletion of GxP-relevant records, with user identity, timestamp, previous value, and new value. Beyond configuration, regular audit trail review is itself a GxP activity. We help organizations design review procedures, define risk-based review frequencies, and train responsible personnel.

Access Control and User Management

GxP access control requirements mandate unique, non-shared credentials for each user; role-based access aligned with job function; the principle of least privilege; documented user provisioning and de-provisioning; and monitoring of unauthorized access attempts.

Backup, Business Continuity, and Disaster Recovery

GxP backup requirements go beyond simple file copies: they demand tested restore procedures, off-site storage, and documented Recovery Time Objectives (RTO) and Recovery Point Objectives (RPO) for every critical system. Business Continuity Plans and Disaster Recovery Plans must be formally tested at defined intervals.

Our Service: Gap Assessment and Remediation

Our structured three-phase service delivers:

  1. Discovery: complete inventory of GxP systems, existing validation documentation, user management records, audit trail configuration, and backup/BCP documentation
  2. Technical and Regulatory Assessment: gap identification against Annex 11 and/or 21 CFR Part 11, with severity classification (Critical / Major / Minor)
  3. Gap Report and Remediation Plan: actionable remediation roadmap with owners, timelines, and completion criteria

Why Dalia IA

  • Dual-framework expertise: EU Annex 11 and FDA 21 CFR Part 11, assessed in a single integrated engagement
  • 20+ years of GxP regulatory assessment and remediation experience
  • Technical and regulatory background in both compliance and IT systems
  • Inspection-ready deliverables for FDA, EMA, AIFA, ANSM
  • Post-remediation support to sustain compliance over time

Frequently Asked Questions

What is the difference between EudraLex Annex 11 and FDA 21 CFR Part 11?

Annex 11 is the EU GMP reference for computerized systems in pharmaceutical manufacturing; 21 CFR Part 11 is the FDA regulation for electronic records and electronic signatures. Annex 11 is more principles-based and explicitly requires supplier assessment; Part 11 is more prescriptive on technical specifics. Both require audit trails, access controls, backup, and system validation.

Does my system need to comply with both Annex 11 and 21 CFR Part 11?

If your organization sells or manufactures pharmaceutical products in both Europe and the United States, yes. Dalia IA provides an integrated assessment that evaluates compliance with both frameworks in a single engagement.

What is an audit trail and why does it matter in GxP?

An audit trail is an automatically generated, tamper-proof record of all changes to GxP electronic records: who did what, when, and what the previous value was. It is an explicit requirement of both Annex 11 and 21 CFR Part 11, and one of the most scrutinized elements during FDA and EMA inspections.

What does a gap assessment for Annex 11 compliance typically cover?

A comprehensive Annex 11 gap assessment covers: system validation status and documentation quality, audit trail configuration and review procedures, access control architecture, password policies, user management processes, backup and restore procedures, business continuity plans, and incident management.

What are the consequences of Annex 11 non-compliance during an inspection?

Annex 11 non-compliance can generate inspection findings of varying severity. Critical findings — such as missing audit trails or uncontrolled access — can block product approvals or result in Warning Letters. Having a documented, in-progress remediation plan substantially mitigates regulatory impact.

Ready to structure your Annex 11 / 21 CFR Part 11 compliance?

Request a free preliminary Gap Assessment. Current state evaluation and action plan delivered promptly.

Contact us